Continuous high-dose ivermectin appears to be safe in patients with acute myelogenous leukemia and could inform clinical repurposing for COVID-19 infection

Leuk Lymphoma. 2020 Oct;61(10):2536-2537. doi: 10.1080/10428194.2020.1786559. Epub 2020 Jul 1.

Authors

Claudio Galvao de Castro Jr¹, Lauro Jose Gregianin^{2

3}, Jan A Burger⁴

Affiliations

¹ Santa Casa de Porto Alegre, Porto Alegre, RS, Brazil.
² Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil.
³ Pediatric Department, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.
⁴ Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

PMID: 32611256
DOI: 10.1080/10428194.2020.1786559

No abstract available

Publication types

Letter
Comment

MeSH terms

Betacoronavirus
COVID-19
Coronavirus Infections*
Drug Repositioning
Humans
Ivermectin*
Leukemia, Myeloid, Acute*
Pandemics*
Pneumonia, Viral*
SARS-CoV-2

Substances

Ivermectin